日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Current usage and challenges of master protocols-based on survey results by ASA BIOP oncology methodology working group master protocol sub-team

当前主方案的使用情况和挑战——基于ASA BIOP肿瘤学方法学工作组主方案子团队的调查结果

期刊:Annals of Translational Medicine
影响因子:
doi:10.21037/atm-21-6139
Li, Xiaoyun; Lu, Chengxing; Broglio, Kristine; Bycott, Paul; Chen, Jie; Jiang, Qi; Lin, Jianchang; Ye, Jingjing; Yin, Jun
肿瘤
肿瘤免疫
发表日期：2022
文献求助 收藏

Efficacy and safety of axitinib in combination with gemcitabine in advanced pancreatic cancer: subgroup analyses by region, including Japan, from the global randomized Phase III trial

阿昔替尼联合吉西他滨治疗晚期胰腺癌的疗效和安全性：来自全球随机III期试验的按地区（包括日本）进行的亚组分析

期刊:Japanese Journal of Clinical Oncology
影响因子:2.2
doi:10.1093/jjco/hyv011
Ioka, Tatsuya; Okusaka, Takuji; Ohkawa, Shinichi; Boku, Narikazu; Sawaki, Akira; Fujii, Yosuke; Kamei, Yoichi; Takahashi, Satori; Namazu, Katsushi; Umeyama, Yoshiko; Bycott, Paul; Furuse, Junji
胰腺癌
肿瘤
肿瘤免疫
发表日期：2015
文献求助 收藏

Randomized phase II study of pemetrexed/cisplatin with or without axitinib for non-squamous non-small-cell lung cancer

培美曲塞/顺铂联合或不联合阿昔替尼治疗非鳞状非小细胞肺癌的随机II期研究

期刊:BMC Cancer
影响因子:3.4
doi:10.1186/1471-2407-14-290
Belani, Chandra P; Yamamoto, Nobuyuki; Bondarenko, Igor M; Poltoratskiy, Artem; Novello, Silvia; Tang, Jie; Bycott, Paul; Niethammer, Andreas G; Ingrosso, Antonella; Kim, Sinil; Scagliotti, Giorgio V
肺癌
细胞生物学
肿瘤
肿瘤免疫
发表日期：2014
文献求助 收藏

Interpreting overall survival results when progression-free survival benefits exist in today's oncology landscape: a metastatic renal cell carcinoma case study

在当今肿瘤治疗格局下，当无进展生存期获益存在时，如何解读总生存期结果：转移性肾细胞癌病例研究

期刊:Cancer Management and Research
影响因子:2.6
doi:10.2147/CMAR.S67249
Tang, Yiyun; Bycott, Paul; Akerborg, Orjan; Jönsson, Linus; Negrier, Sylvie; Chen, Connie
肿瘤
肾癌
肿瘤免疫
细胞生物学
发表日期：2014
文献求助 收藏

A Phase II trial of axitinib in patients with various histologic subtypes of advanced thyroid cancer: long-term outcomes and pharmacokinetic/pharmacodynamic analyses

阿昔替尼治疗不同组织学亚型晚期甲状腺癌患者的II期试验：长期疗效及药代动力学/药效学分析

期刊:Cancer Chemotherapy and Pharmacology
影响因子:2.3
doi:10.1007/s00280-014-2604-8
Cohen, E E W; Tortorici, M; Kim, S; Ingrosso, A; Pithavala, Y K; Bycott, P
甲状腺癌
肿瘤
肿瘤免疫
免疫/内分泌
发表日期：2014
文献求助 收藏

Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study

阿昔替尼对所有组织学亚型的晚期甲状腺癌均有效：一项 II 期研究的结果

期刊:Journal of Clinical Oncology
影响因子:41.9
doi:10.1200/JCO.2007.15.9566
Cohen, Ezra E W; Rosen, Lee S; Vokes, Everett E; Kies, Merrill S; Forastiere, Arlene A; Worden, Francis P; Kane, Madeleine A; Sherman, Eric; Kim, Sinil; Bycott, Paul; Tortorici, Michael; Shalinsky, David R; Liau, Katherine F; Cohen, Roger B
甲状腺癌
肿瘤
肿瘤免疫
免疫/内分泌
发表日期：2008
文献求助 收藏